Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (Ã-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
IPO Year: 2020
Exchange: NASDAQ
Website: passagebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2024 | $7.00 | Buy | Rodman & Renshaw |
| 3/8/2022 | Overweight → Neutral | JP Morgan | |
| 3/4/2022 | $29.00 → $24.00 | Outperform | Raymond James |
| 1/19/2022 | $29.00 → $6.00 | Buy → Neutral | Goldman |
| 7/1/2021 | $29.00 | Outperform | Raymond James |
10-Q - Passage BIO, Inc. (0001787297) (Filer)
8-K - Passage BIO, Inc. (0001787297) (Filer)
8-K - Passage BIO, Inc. (0001787297) (Filer)
144 - Passage BIO, Inc. (0001787297) (Subject)
144 - Passage BIO, Inc. (0001787297) (Subject)
8-K - Passage BIO, Inc. (0001787297) (Filer)
8-K - Passage BIO, Inc. (0001787297) (Filer)
8-K - Passage BIO, Inc. (0001787297) (Filer)
10-Q - Passage BIO, Inc. (0001787297) (Filer)
8-K - Passage BIO, Inc. (0001787297) (Filer)
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines comp
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio's website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event. About Passage Bio Passage Bio (NASDAQ:PASG) is a clinical stage genetic medicines co
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation in Grn knockout mice, and achieved widespread vector distribution throughout the nervous system in non-human primates Company delivered data during an oral presentation on Thursday, October 24 at ESGCT PHILADELPHIA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the company delivered precli
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio's website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event. About Passage Bio Passage Bio (NASDAQ:PASG) is a clinical stage genetic medicines compa
Interim safety and biomarker data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 of PBFT02 achieved robust levels of CSF progranulin in all treated Cohort 1 patients; elevated CSF progranulin levels were sustained up to 12 months post-treatment Dose 1 of PBFT02 continued to be well-tolerated in all patients who received a revised immunosuppression regimen Company to deliver the updated data during a poster presentation at ISFTD2024 on Friday, September 20, 2024 at 9:38 a.m. GMT PHILADELPHIA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio's website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event. About Passage Bio Passage Bio (NASDAQ:PASG) is a clinical stage genetic medicines
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Completed out-licensing of pediatric lysosomal storage disease programs to GEMMA Biotherapeutics Strong balance sheet to support continued execution, with cash runway to fund operations extended to the end of Q2 2026 PHILADELPHIA, Aug. 08
PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 44th Annual Growth ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Tuesday, August 13, 2024Presentation Time: 8:00 a.m. ET Location: Boston, MA 15th Annual Wedbush PacGrow Healthcare ConferenceFormat: Management will participate in investor meetingsDate: Wednesday, August 14, 2024Location: New York City, NY A live webcast of the presen
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson Entered new strategic research and collaboration agreement with GEMMA Biotherapeutics to advance genetic medicines for CNS indications, including Huntington's disease Transaction expected to extend operating cash runway to the end of Q2 2026 PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative
SC 13G - Passage BIO, Inc. (0001787297) (Subject)
SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)
SC 13G/A - Passage BIO, Inc. (0001787297) (Subject)
SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)
SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)
SC 13G - Passage BIO, Inc. (0001787297) (Subject)
SC 13G/A - Passage BIO, Inc. (0001787297) (Subject)
SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)
SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)
SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)
4 - Passage BIO, Inc. (0001787297) (Issuer)
4 - Passage BIO, Inc. (0001787297) (Issuer)
3 - Passage BIO, Inc. (0001787297) (Issuer)
4 - Passage BIO, Inc. (0001787297) (Issuer)
4 - Passage BIO, Inc. (0001787297) (Issuer)
3 - Passage BIO, Inc. (0001787297) (Issuer)
4 - Passage BIO, Inc. (0001787297) (Issuer)
4 - Passage BIO, Inc. (0001787297) (Issuer)
4 - Passage BIO, Inc. (0001787297) (Issuer)
4 - Passage BIO, Inc. (0001787297) (Issuer)
Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partnership opportunities for clinical-stage pediatric lysosomal storage disease programs including GM1 gangliosidosisManagement to host a webcast presentation to review interim FTD data today at 8:30 a.m. ET
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β-Gal activity and GM1 gangliosides, similar to healthy controlsDose 2 biomarker responses demonstrated durability up to 12 months after treatmentImagine-1 study participants showed initial evidence of improved survival relative to natural history dataTreated first patient at highest dose level, Dose 3, in July; initial safety and biomarker data from Dose 3 expected by mid-2024Management to host a conference call and webcast today at 8:30 a.m. ET
Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023Planned expansion of Imagine-1 study to treat patients at a higher dose; expect to dose first patient in second half of 2023Plan to report initial safety and biomarker data from Cohort 1 of global upliFT-D trial for frontotemporal dementia in the second half of 2023Ended 2022 with strong cash position; cash runway into the first half of 2025Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, March 06, 2023 (GLOBE NEW
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 6, 2023 to report its fourth quarter and full-year 2022 financial results and discuss recent business highlights. To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call. About Passage BioPassage Bio (NASDAQ:
Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna administration of PBGM01 resulted in dose-dependent increases in CSF β-Gal activity and decreases in CSF GM1 gangliosidesPBGM01 administration resulted in a meaningful improvement across developmental areas in a subset of patients, as assessed by investigators and caretakersCompleted dosing of all patients in dose-ascending portion of study; initial safety and biomarker data from Cohort 4 expected by mid-2023Management to host a conference call and webcast today at 8:30 a.m. ET PHILADELPHIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc
Dosed first patient in final cohort, Cohort 4, in dose-ascending phase of Imagine-1 clinical trial for GM1 gangliosidosis; expect to dose the final patient in this phase of the trial by year-endPlan to report initial safety and biomarker data from Cohorts 2 and 3 of Imagine-1 trial in December 2022Dosed first patient in Cohort 1 of upliFT-D clinical trial for frontotemporal dementiaCompany to streamline operations and refocus strategy, advancing Imagine-1 clinical trial for GM1 gangliosidosis,upliFT-D clinical trial for frontotemporal dementia and preclinical pipeline in adult CNS indicationsCash runway extended into 1H 2025 Management to host conference call today at 8:30 a.m. ET PHILADELP
PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 10, 2022, to report its third quarter 2022 financial results and discuss recent business updates. To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call. About Passage BioPassage Bio (NASDAQ:PASG) is a
Advanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase of study following recommendation by Independent Data Monitoring Committee Presented encouraging longer-term clinical and biomarker data from Cohort 1 in Imagine-1 study at ASGCT; interim safety and biomarker data for Cohorts 2 and 3 expected in 2H22Received IND clearance for Phase 1 clinical program of PBML04 for metachromatic leukodystrophyEnded 2Q22 with strong cash position; cash on hand to fund operations into 2Q24Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinica
PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results and discuss recent business highlights. To access the live conference call and webcast, please register here. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call. About Passage Bio Passage Bio (NASDAQ:PASG) is
Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22Dosed first patient in Cohort 1 in GALax-C clinical trial in infantile Krabbe disease; interim safety and biomarker data expected by year-end 2022Submitted IND for Phase 1/2 clinical program of PBML04 for metachromatic leukodystrophy Completed strategic prioritization to extend cash runway into 2Q24Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformat
Rodman & Renshaw initiated coverage of Passage BIO with a rating of Buy and set a new price target of $7.00
JP Morgan downgraded Passage Bio from Overweight to Neutral
Raymond James reiterated coverage of Passage Bio with a rating of Outperform and set a new price target of $24.00 from $29.00 previously
Goldman downgraded Passage BIO from Buy to Neutral and set a new price target of $6.00 from $29.00 previously
Raymond James initiated coverage of Passage Bio with a rating of Outperform and set a new price target of $29.00
BTIG initiated coverage of Passage Bio with a rating of Buy and set a new price target of $25.00
Chardan Capital reiterated coverage of Passage Bio with a rating of Buy and set a new price target of $45.00 from $35.50 previously
The Goldman Sachs Group upgraded Passage Bio from Neutral to Buy and set a new price target of $30.00 from $28.00 previously
Chardan Capital reiterated coverage of Passage Bio with a rating of Buy and set a new price target of $45.00 from $35.50 previously
The Goldman Sachs Group upgraded Passage Bio from Neutral to Buy and set a new price target of $30.00 from $28.00 previously
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $14 to $13.
Canaccord Genuity analyst Whitney Ijem reiterates Passage Bio (NASDAQ:PASG) with a Buy and maintains $14 price target.
Appointed Kathleen Borthwick as Chief Financial Officer, effective March 1, 2024: Ms. Borthwick previously served as the company's Senior Vice President, Finance and Interim CFO and brings 25 years of pharmaceutical and biotech strategic financial leadership experience.
Gainers Inspire Veterinary (NASDAQ:IVP) stock moved upwards by 178.9% to $0.52 during Friday's pre-market session. The company's market cap stands at $5.7 million. Aclarion (NASDAQ:ACON) stock increased by 115.01% to $4.01. The company's market cap stands at $3.3 million. Panbela Therapeutics (NASDAQ:PBLA) stock increased by 61.23% to $5.24. The market value of their outstanding shares is at $2.5 million. Corbus Pharmaceuticals (NASDAQ:CRBP) stock rose 25.48% to $10.59. The company's market cap stands at $46.8 million. NeuBase Therapeutics (NASDAQ:NBSE) shares rose 20.92% to $0.75. The company's market cap stands at $2.7 million. Ainos (NASDAQ:AIMD) shares moved upwards by 19.07% to $1
Gainers Cadrenal Therapeutics (NASDAQ:CVKD) shares moved upwards by 8.5% to $1.15 during Monday's after-market session. The market value of their outstanding shares is at $14.9 million. vTv Therapeutics (NASDAQ:VTVT) shares moved upwards by 6.98% to $9.95. The company's market cap stands at $20.2 million. Passage Bio (NASDAQ:PASG) stock increased by 6.94% to $0.97. The market value of their outstanding shares is at $53.1 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 6.08% to $2.44. The market value of their outstanding shares is at $1.6 million. Brainstorm Cell (NASDAQ:BCLI) stock increased by 5.76% to $0.31. The market value of their outstanding shares is at $15
Gainers Talphera (NASDAQ:TLPH) stock moved upwards by 10.5% to $0.85 during Wednesday's after-market session. The company's market cap stands at $14.4 million. Windtree Therapeutics (NASDAQ:WINT) shares moved upwards by 9.01% to $0.53. The market value of their outstanding shares is at $2.7 million. Passage Bio (NASDAQ:PASG) shares rose 7.02% to $0.98. The market value of their outstanding shares is at $53.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock rose 5.8% to $3.37. The market value of their outstanding shares is at $20.5 million. Biora Therapeutics (NASDAQ:BIOR) stock increased by 5.5% to $1.15. The company's market cap stands at $31.2 million. Coeptis Therapeutics (NASDAQ:COE
Gainers Aclarion (NASDAQ:ACON) shares rose 70.0% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $4.6 million. TRACON Pharma (NASDAQ:TCON) shares moved upwards by 47.92% to $0.28. The company's market cap stands at $8.6 million. Eterna Therapeutics (NASDAQ:ERNA) stock moved upwards by 22.8% to $1.87. The market value of their outstanding shares is at $10.0 million. Passage Bio (NASDAQ:PASG) shares increased by 21.23% to $0.92. The market value of their outstanding shares is at $50.4 million. NuCana (NASDAQ:NCNA) stock moved upwards by 16.6% to $0.4. The company's market cap stands at $21.2 million. Regional Health Props (AMEX:RHE) stock
Shares of BlackBerry Limited (NYSE:BB) moved lower in pre-market trading following the release of third-quarter results. BlackBerry reported quarterly earnings of 1 cent per share which exceeded the Street's estimate of losses of 3 cents per share, according to Benzinga Pro. The company also said it sees fourth-quarter revenue of $150 million to $159 million. BlackBerry shares fell 5.4% to $3.88 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Infrared Cameras Holdings Inc (NASDAQ:MSAI) rose 213% to $8.20 in pre-market trading after falling over 61% on Wednesday. Mobile Global Esports Inc.(NASDAQ:MGAM) gained 53.4% to $0.4294 in pre-market tra
Passage Bio Inc (NASDAQ:PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with granulin (GRN) mutations. FTD is a form of early-onset dementia (memory loss). Dose 1 of PBFT02 was generally well-tolerated in patients 2 and 3, who received an enhanced steroid regimen following protocol amendment. Patient 1 received a low level of immunosuppression and experienced two SAEs that were both asymptomatic and consistent with an immune response. Following patient 1, the protocol was amended to increase t
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines comp
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission
Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-2024Expect to present initial safety and biomarker data from Cohort 1 in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 202
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of Dolan Sondhi, Ph.D., to the Board of Directors and her appointment to the Nominating and Corporate Governance Committee. Dr. Sondhi is currently Professor of Research in the Department of Genetic Medicine at Weill Cornell Medicine. Additionally, Thomas Woiwode, Ph.D., announced his resignation from the Board of Directors to focus on his Managing Director role within Versant Ventures. "We are thrilled to welcome Dr. Dolan Sondhi to Passage Bio'
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief executive officer (CEO) and a member of the board, effective immediately. Edgar B. (Chip) Cale will resign his position as the company's interim CEO and will continue in his role as general counsel and corporate secretary. Maxine Gowen, Ph.D., will step down as interim executive chairwoman following a brief transition period and will then continue to serve as chairwoman. "The Board and I are delighted to welcome W
PHILADELPHIA, July 06, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of Michael Kamarck, Ph.D., to its board of directors and his appointment to the Nominating and Corporate Governance Committee. Dr. Kamarck is a seasoned biopharmaceutical executive with over forty years of experience in discovery research, process development and technical operations. "We are thrilled to welcome Michael to our board as we continue to advance our clinical programs in our mission to bring transformative therapies to patients with C
Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition periodEdgar B. (Chip) Cale, current general counsel and corporate secretary, appointed as interim chief executive officer PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced today that the board of directors and Bruce Goldsmith, Ph.D. have mutually agreed that Dr. Goldsmith will step down as president and chief executive officer and a member of the board, effe
Eleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertise building high-growth, high-impact life science companies complements Eleusis's world-class leadership team. The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC Pharmaceuticals Esther van den Boom, Managing Partner at van den Boom & Associates "We are delighted to welcome these four exceptional d
PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced it has appointed Eliseo O. Salinas, M.D., MSc, as the company’s chief research & development (R&D) officer. Dr. Salinas joins the company from Acadia Pharmaceuticals, where he served as chief scientific officer (CSO) and senior vice president, External Innovation. “As Passage Bio continues to grow and evolve, building its pipeline of genetic medicines and transitioning to a clinical-stage company with multiple assets in the clinic, we are pleased to have some
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate. Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio. Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new